Citations

Clear

187 citation(s) found for "Ha, Gavin".

Impact of Metabolic Syndrome on Cataracts: A Systematic Review and Meta-Analysis
Tirakunwichcha, Pawaris, Phutinart, Somkiat , Pajareya, Patavee , Winson, Chanissara, Roddy, Gavin W. , Pajareya, Patavee , Siranart, Noppachai , Nakaphan, Pannathorn

Mayo Clinic

Metabolic Syndrome and Related Disorders | January 13, 2026 | Volume: 24 | Issue: 2 | Pages: 57-64

10.1177/15578518251407586 | PMID 41824392 Get It

Cataracts are the leading cause of blindness worldwide. Obesity, a key component of metabolic syndrome (MetS), may represent a modifiable risk factor for cataracts. However, the evidence regarding the association between MetS or its components and cataracts remains controversial. Therefore, our meta-analysis aims to clarify the relationship between MetS or its components and cataracts. A search was conducted until February 2024 via the MEDLINE, EMBASE, and Cochrane databases. The primary endpoint included the association between MetS or its components, including body mass index (BMI), diabetes mellitus (DM), hypertension (HT), and dyslipidemia (DLP), and cataracts. Secondary endpoints included the association between levels of blood pressure, blood sugar, and lipid profiles and cataracts. A total of 27 studies were included with a total of 1,010,014 patients (134,498 with cataracts and 875,516 without cataracts). Of these, there were 2 prospective cohort studies, 6 case–control studies, and 19 cross-sectional studies. The prevalence of cataracts was 13.3%. MetS was significantly associated with cataracts with an odds ratio (OR) of 1.60 (95% confidence interval [CI]: 1.44–1.77, I 2 = 93%). Among MetS components, high BMI and being diagnosed with DM, HT, and DLP were associated with cataracts with ORs of 1.45 (95% CI: 1.33–1.58, I 2 = 80%), 1.77 (95% CI: 1.69–1.85, I 2 = 51%), 1.23 (95% CI: 1.19–1.28, I 2 = 62%), and 1.38 (95% CI: 1.30–1.46, I 2 = 0%). Among the metabolic parameters, high total cholesterol, high triglycerides, low high-density lipoprotein cholesterol, and high low-density lipoprotein cholesterol were associated with cataracts with ORs of 1.25 (95% CI: 1.04–1.49, I 2 = 48%), 1.05 (95% CI: 1.04–1.06, I 2 = 68%), 1.07 (95% CI: 1.01–1.13, I 2 = 0%), and 1.30 (95% CI: 1.10–1.53, I 2 = 71%), respectively. MetS, obesity, DM, HT, and DLP are associated with cataracts. Prevention or treatment of MetS or its components likely represent a modifiable risk factor in cataract development.
Outside-In Capsulotomy for Intra-articular Hip Access
Ina, Jason , Rosenow, Christian S. , Levy, Bruce A., Krych, Aaron J., Hevesi, Mario, Hevesi, Mario , Ina, Jason G , Hevesi, Mario , Ward, Gavin H. , Levy, Bruce A. , Krych, Aaron J.

Mayo Clinic

Video Journal of Sports Medicine | January 12, 2026 | Volume: 6 | Issue: 1 | Pages: No page available

10.1177/26350254251351034 | PMID 41536923 Get It

Background: Arthroscopic treatment of excessive acetabular coverage with pincer morphology or coxa profunda can be challenging. In patients with excessive acetabular coverage with nondistractible hips, an outside-in capsuolotomy can be considered to gain safe and efficient intra-articular access to the hip. Indications: The indications for an outside-in capsulotomy include patients with acetabular retroversion, a lateral center-edge angle >40°, coxa profunda or protrusio, or stiff, older male patients who remain hip preservation candidates. Technique Description: The outside-in capsulotomy is performed once it is recognized that traction on the operative extremity will not provide adequate working space for safe intra-articular access. Traction is taken off the operative extremity, and an anterolateral portal is localized to the 12:00 position on the hip joint with the use of fluoroscopy. The camera is then placed in a juxta-capsular location, and a modified anterior portal is created under direct arthroscopic visualization. We then proceed with extracapsular dissection to identify the indirect head of the rectus. An outside-in capsulotomy is then performed parallel to the indirect head of the rectus, approximately 5 mm distal to its insertion on the acetabular rim. Prior to deep completion of the capsulotomy, the hip joint is flexed to 30° to protect the articular cartilage of the femoral head. Once intra-articular access is obtained, traction can be reapplied, and one can proceed with hip arthroscopy in a standard fashion. Results: This technique decreases the traction time needed, given that the capsulotomy is performed without traction applied. Additionally, the amount of force required for hip distraction is decreased once the capsuolotomy has been completed, through usual sectioning of the iliofemoral ligament. The presented technique is both safe and efficacious, with no published difference in complications as compared to standard inside-out access. A published series of patients with severe pincer morphology and lateral overcoverage who undergo hip arthroscopy with outside-in access demonstrates satisfactory postoperative improvements in patient-reported outcome measures. Discussion/Conclusion: The outside-in capsulotomy provides a means for safe access to the hip joint in otherwise limited or nondistractible hips.
The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors
Alexander, S P H , Fabbro, Doriano , Peach, Chloe J. , Gibb, Alasdair J. , Kelly, Eamonn , Mathie, Alistair , Veale, Emma L. , Armstrong, Jane F , Faccenda, Elena , Harding, Simon D , Beuve, Annie, Brouckaert, Peter, Burnett, John C., Friebe, Andreas, Garthwaite, John, Hobbs, Adrian J., Koesling, Doris, Kuhn, Michaela, Leitinger, Birgit , Potter, Lincoln R., Russwurm, Michael, Schmidt, Harald H. H. W., Stasch, Johannes‐Peter, Waldman, Scott A., Alexander, Stephen P H , Mathie, Alistair A , Southan, Christopher , Davies, Jamie A , Bryant, Clare , Farndale, Richard W , Jarvis, Gavin E , Kilpatrick, Laura , Leitinger, Birgit , MacEwan, David , Monie, Tom P , Veale, Emma L , Armstrong, Jane F , Faccenda, Elena , Harding, Simon D , Peach, Chloe J. , Gibb, Alasdair J. , Kelly, Eamonn , Beuve, Annie , Brouckaert, Peter, Burnett, John C., Farndale, Richard, Friebe, Andreas , Garthwaite, John, Hobbs, Adrian J., Koesling, Doris , Kuhn, Michaela, Potter, Lincoln R., Russwurm, Michael, Schmidt, Harald , Stasch, Johannes‐Peter, Waldman, Scott A.

Mayo Clinic

British Journal of Pharmacology | December 30, 2025 | Volume: 182 | Issue: S1 | Pages: No page available

10.1111/bph.70233 | PMID 41461584 Get It

The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear, accessible, and well‐structured, rather than the scope of the content, which spans approximately 500 pages. The Concise Guide summarises the key pharmacological properties of around 1900 human drug targets, and nearly 7000 interactions, involving around 4400 ligands. While the content is a substantially condensed version of the more detailed information and links available at the www.guidetopharmacology.org website, the printed guide serves as a permanent, citable, point‐in‐time record, that remains stable despite ongoing updates to the online database. The full contents of this publication can be found at https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.70233 . The Concise Guides provide expert‐curated recommendations of ‘Gold Standard’ selective pharmacological tools, available either commercially or as donations, which enable the identification of individual drug targets or families of drug targets. While the Concise Guide offers a more streamlined overview, more comprehensive information, including detailed pharmacological profiles and links to multiple online databases, is available through the Guide to Pharmacology website. The 2025/26 edition of the Concise Guide is based on material current as of mid‐2025, and supersedes all previous editions, including the 2023/24 Guide, and earlier Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), and as such provides official IUPHAR classification and nomenclature for human drug targets, where applicable. Catalytic receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein‐coupled receptors, ion channels, nuclear hormone receptors, enzymes and transporters. Each section includes nomenclature guidance, concise summaries, information of the best available pharmacological tools, key references, and suggestions for further reading.
EP87 The Less of the Lesser Sign: Posterolateralization of the Lesser Trochanter was Associated with Symptomatic Iliopsoas Tendinitis following Total Hip Arthroplasty
Broida, Sam, Iyer, Sanathan , Taunton, Michael, Spencer-Gardner, Luke, Pagnano, Mark, Ward, Gavin H. , Bingham, Joshua S. , Taunton, Michael J. , Spencer-Gardner, Luke , Hevesi, Mario

Mayo Clinic

Journal of Hip Preservation Surgery | December 22, 2025 | Volume: 12 | Issue: Supplement_2 | Pages: ii70-ii70

10.1093/jhps/hnaf069.219 Get It

Abstract Purpose Iliopsoas tendinitis following total hip arthroplasty (THA) has been described to result from acetabular component overhang as well as prominent femoral collars. Yet, a portion of patients experience iliopsoas tendinitis in the setting of well-positioned components. The purpose of this study was to assess anatomic factors predisposing to iliopsoas tendinitis after THA. Methods Patients with THAs performed at three academic institutions who subsequently underwent arthroscopic iliopsoas release were retrospectively reviewed from 2015 to 2025 and propensity matched in a 1:3 fashion to a control group of THAs without subsequent iliopsoas release. Controls were matched by age, surgery date, laterality, sex, surgical approach, and implanted femoral component. Patients with iliopsoas tendinitis and subsequent release (THA-IP) were evaluated for anterior acetabular component overhang and femoral collar overhang, when a collar was present. We also evaluated the absolute and relative profile of the lesser trochanter on anteroposterior radiographs, understanding that when less of the lesser trochanter is visualized, the trochanter is anatomically displaced posterolaterally, resulting in a more arduous route from the inner pelvic origin of the iliopsoas to its insertion on the femur. Results Forty-five patients (mean age: 57±11; 71% female; 19 direct anterior, 10 anterolateral, 16 posterior approach) undergoing THA-IP were analyzed and matched to 135 controls. Both groups demonstrated a median cup size of 54 mm and head size of 36 mm. Average time to iliopsoas release after THA was 4 years. Anterior cup overhang of >2 mm was present in 49% of THA-IP patients, with 18% having collared femoral components, and 9% demonstrating collar overhang of >2 mm. Overall, 19 THA-IP patients had <2 mm of cup and collar overhang and 26 patients had >2 mm of overhang. THA-IP patients with <2 mm of cup and collar overhang had significantly greater relative posterolateralization of the lesser trochanter compared to those with overhang of >2 mm (p=0.010) and to controls (p=0.037). Conclusion Visualizing “Less of the Lesser” on anteroposterior hip radiographs and associated posterolateralization of the lesser trochanter may be an anatomic risk factor for iliopsoas tendinitis following THA, even in the presence of satisfactorily positioned components.
FP9.4 Clinical Outcomes of Arthroscopic Iliopsoas Fractional Lengthening after Total Hip Arthroplasty: A Prospective Study
Iyer, Sanathan , Alshaibi, Rakan , Ahmed, Rana Ali, Yanamala, Sandeep , Levy, Bruce, Cabarcas, Brandon C. , Ina, Jason , Ward, Gavin H. , Daniel, Adam V. , Hevesi, Mario

Mayo Clinic

Journal of Hip Preservation Surgery | December 22, 2025 | Volume: 12 | Issue: Supplement_2 | Pages: ii16-ii16

10.1093/jhps/hnaf069.047 Get It

Abstract Purpose To investigate clinical outcomes, including patient reported outcome measures (PROMs), subjective anterior groin pain and hip flexion strength, and reoperation rates following arthroscopic iliopsoas fractional lengthening after total hip arthroplasty (THA). Methods Patients who were indicated for arthroscopic iliopsoas fractional lengthening after ipsilateral THA were prospectively identified between 2023-2025 at a single institution. Pre- and post-operative PROMs, including Visual Analog Scale (VAS), Tegner activity scale, Single Assessment Numeric Evaluation (SANE), and subjective anterior groin pain and hip flexion strength were analyzed. Reoperations at final follow-up were also evaluated. Results A total of 44 hips in 41 patients (23 females and 18 males) were included (mean age: 64.7 ± 10.2, mean BMI: 29.9 ± 5.9 kg/m2). Fifty-five percent of patients underwent surgery on their right hip. The mean postoperative follow-up timeframe was 10.0 ± 7.1 months. There was a significant improvement in postoperative PROMs compared to pre-operative levels for VAS at rest (1.3 ± 1.9 vs. 2.9 ± 2.2), VAS with use (3.1 ± 3.8 vs. 8.0 ± 1.6), Tegner activity scale (2.9 ± 1.3 vs. 2.1 ± 1.1), and SANE (74.0 ± 20.3 vs. 47.9 ± 23.4) (p<0.001 for all). Over 90% of patients reported feeling much better or slightly better regarding their anterior groin pain at 2-weeks post-operatively (93%), 6 weeks post-operatively (90%), 3 months post-operatively (93%), and at final follow-up (91%). Regarding hip flexion strength, 73% reported feeling much better or slightly better at 2-weeks post-operatively, 95% at 6-weeks post-operatively, 85% at 3 months post-operatively, and 61% at final follow-up. Only 2 patients (5%) reported feeling much weaker at final follow-up. Two of 44 hips (5%) underwent reoperation at final follow-up. One patient underwent a 2-stage revision THA at 5 months postoperatively due to infection, while 1 patient underwent an open iliopsoas release with acetabular screw removal and liner exchange. Overall, the mean surgery satisfaction was 8.1 ± 2.6 on a scale of 1-10. Conclusion Patients who underwent arthroscopic iliopsoas fractional lengthening following THA demonstrated satisfactory postoperative outcomes, with over 90% reporting durably improved anterior groin pain and nearly two-thirds reporting increased hip flexor strength throughout follow-up.
Estrogen exposure from modern contraceptives and vascular risk in women with migraine: A nationwide electronic medical record database study
Ihara, Keiko , Pike, C. William , Hui, Gavin , Jackson, Michael L. , Tietjen, Gretchen E. , Chiang, Chia‐Chun , Chiang, Chia-Chun , Gombar, Saurabh , Callahan, Alison

Mayo Clinic

Cephalalgia | December 17, 2025 | Volume: 45 | Issue: 12 | Pages: No page available

10.1177/03331024251404924 | PMID 41406065 Get It

Background Many guidelines list migraine with aura (MwA) as a contraindication to estrogen-containing combined hormonal contraceptives (CHCs) due to vascular risks. However, current evidence is based on small sample studies with potential influence by confounding factors. Additionally, few studies have examined the vascular risk associated with modern CHCs with lower dose estrogen, particularly in relation to aura status. The present study aims to investigate the vascular risk of modern CHCs in women with migraine with and without aura. Methods We used a de-identified electronic medical record database with 120 million patients across multiple health systems in the United States of America. We included female patients aged 18–45 years who received a migraine diagnosis code, had at least three office visits within three years, and were prescribed at least one migraine-specific medication within 6 months following the first outpatient visit. All data after 2010 were included. Patients with prior cardiovascular events were excluded. Our composite endpoint consisted of acute ischemic stroke, acute myocardial infarction, deep vein thrombosis/pulmonary embolism and intravenous thrombolytic administration. We stratified our analysis according to CHC exposure and aura status and compared the incidence of the endpoint with high-dimensional propensity score-matching between CHC users and non-users in (i) the overall cohort, (ii) MwA and (iii) migraine without aura (MwoA); between MwA and MwoA in (iv) patients prescribed CHCs; and in (v) those without CHC prescriptions. Results We included 5535 patients who received CHC prescriptions and 21,520 who did not. 114 (2.06%) of CHC users and 547 (2.54%) of CHC non-users had at least one vascular event. With propensity score-matched comparison, the composite endpoint did not significantly differ between CHC and non-CHC in the overall migraine group, those with MwA and the MwoA group. In those prescribed CHC, MwA and MwoA did not differ in all the outcomes. For CHC non-users, MwA was associated with a higher incidence of acute ischemic stroke (hazard ratio = 2.45; 95% confidence interval = 1.58–3.78; p < 0.001; n = 6201 in each group) and the composite endpoint (hazard ratio = 1.34; 95% confidence interval = 1.08–1.67; p = 0.008). Conclusions Our real-world study showed that exposure to modern CHC was not associated with a significant increase in vascular risk in women aged 18–45 years with migraine, MwA or MwoA who have no prior cardiovascular events. However, in those who never received CHC, MwA was associated with higher vascular risks compared to MwoA. While limitations exist using large scale electronic medical record databases for analysis, our results suggest that carefully designed prospective studies should be conducted to reassess the vascular risk associated with CHC use in women with migraine, especially MwA.
Optimizing procedures for ocular radiation injury studies in the tree shrew
Dalvin, Lauren A. , Anderson, Kjersten J. , Rinkoski, Tommy A. , Miley, David R. , Ong, Hien Thi My , Schechinger, Angela M., Fjeld, Cassandra A., Leblond, Catherine R. , Keown, Mackenzie K. , Palmer, Sierra D. , Carlson, Brett L. , Ott, Lauren L. , Romero, Michael F. , Boynton, Felicia D. Duke , Roddy, Gavin W. , Ong, Hien , Burgenske, Danielle M , Carlson, Brett L , Ott, Lauren L , Samuels, Brian C , Romero, Michael F , Sarkaria, Jann N , Boynton, Felicia Duke , Roddy, Gavin W , Dalvin, Lauren A , Burgenske, Danielle M. , Sarkaria, Jann N.

Mayo Clinic

Exploration of Targeted Anti-tumor Therapy | December 2, 2025 | Volume: 6 | Issue: No issue available | Pages: No page available

10.37349/etat.2025.1002352 | PMID 41357135 Get It

Radiation exposure to the eye during cancer treatment can lead to ocular radiation injury (ORI), a devastating condition that can have a profound and permanent impact on vision-related quality of life. Rodent models do not have adequate ocular anatomy to accurately simulate human ORI, and modeling in non-human primates is limited by logistical and ethical concerns. To improve future translational research investigating ways to treat or prevent ORI, we developed protocols for a tree shrew model of ORI. Northern tree shrews (Tupaia belangeri) were obtained by our laboratory. Custom housing and handling methods were developed, including custom body suits to maintain the tree shrew’s body temperature during procedures. Radiation delivery was optimized to accurately deliver radiation, and imaging was performed to observe fundus changes from ORI. Optimization of tree shrew handling, housing, anesthesia approaches, radiation delivery, and clinically-relevant ocular imaging permitted successful induction and assessment of ORI in tree shrews. With these protocols, tree shrews can be used as a highly relevant model organism with key anatomic features similar to humans to study ORI.
EXTH-18. MT-125 Inhibits Non-Muscle Myosin IIA and IIB and Prolongs Survival in Glioblastoma
Rosenfeld, Steven S. , Kenchappa, Rajappa S., Canoll, Peter, Dovas, Athanassios, Rumbaugh, Gavin , Griffin, Patrick , Miller, Courtney , Radnai, László , Zarco, Natanael , Griffin, Patrick, Kamenecka, Theodore M.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v342-v342

10.1093/neuonc/noaf201.1352 Get It

Abstract The prognosis for patients afflicted with GBM has remained dismal in spite of decades of investigations, which speaks to the need to identify targets that drive essential functions in GBM, using well-tolerated, brain permeant inhibitors. Here we report our studies of MT-125, a small molecule inhibitor of non-muscle myosin IIA and IIB. MT-125 has high brain penetrance and an excellent safety profile; blocks GBM invasion and cytokinesis; and prolongs survival in murine GBM models. By impairing mitochondrial fission, MT-125 increases redox stress and induces DNA damage and ferroptosis; and these effects explain why this drug synergizes with radiotherapy in prolonging survival in murine GBM models. MT-125 also induces oncogene addiction to receptor tyrosine kinase (RTK) signaling through a mechanism that is also driven by redox stress, and it also synergizes with FDA-approved RTK and MAP Kinase pathway inhibitors in vitro. Furthermore, MT-125 also synergizes with an FDA approved, RTK inhibitor in vivo, with the combination producing long-term, tumor free survival in an aggressive, preclinical murine model of GBM. MT-125’s long-term administration is well-tolerated at doses well above what is predicted to be therapeutic in multiple mammalian species. These data provide a powerful rationale for the clinical development of NMII targeting therapeutics to treat cancer and demonstrates that MT-125 has strong clinical potential for the treatment of GBM.
CTIM-33. PERSONALIZED MULTIVALENT DNA VACCINATION SAFELY INDUCES BROAD NEOANTIGEN-SPECIFIC T CELL RESPONSES IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN A CLINICALLY RELEVANT TIME SCALE
Yan, Jian , Navarro, Jaye , Paxton, Sophia A. , Cooch, Neil , Rochestie, Sarah, Peters, Joann, Campian, Jian , Junker, Beth, Chheda, Milan G. , Zipfel, Gregory J. , Dowling, Joshua L. , Gillanders, William E. , Sardesai, Niranjan, Dunn, Gavin P. , Johanns, Tanner M. , Garfinkle, Elizabeth A.R. , Perales-Linares, Renzo F. , Gimple, Ryan C. , Livingstone, Alexandra J. , Roberts, Kaleigh F. , Perales‐Puchalt, Alfredo , Chicoine, Michael , Kim, Albert H. , Willie, Jon T , Miller, Katherine E. , Mardis, Elaine R.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v122-v122

10.1093/neuonc/noaf201.0490 Get It

Abstract Glioblastoma is a highly lethal malignancy with dismal overall survival and near universal recurrence despite maximal multimodal therapy. Patients with unmethylated O6-methylguanine methyltransferase (MGMT) promoters do not derive survival benefit from adjuvant temozolomide. Immunotherapies have revolutionized cancer care; however, this modality has yet to translate into survival benefits in glioblastoma in part due to both local and systemic immunosuppressive states. Here, we report the results of a phase 1 clinical trial (NCT04015700) evaluating the safety and feasibility of GNOS-PV01, a personalized DNA vaccination platform that safely immunized against up to 40 patient-specific neoantigens in a clinically relevant timescale following surgical resection and radiation for MGMT-unmethylated glioblastoma patients. Multisector tumor sampling at time of resection enabled personalized and spatially representative neoantigen identification through an established pipeline. In the nine participants receiving vaccines, there were no unexpected toxicities or serious adverse events with a median vaccine delivery time of 10 weeks post-radiation. The vaccination was strongly immunogenic and induced activation and expansion of both local infiltrating CD8+ and CD4+ T-cells and circulating peripheral T-cells. T-cell receptor sequencing revealed both expanded pre-existing populations as well as novel neoantigen-specific populations, suggesting that vaccination both reinvigorates pre-existing immunity and generates novel immune reactivity. We developed a new technology to profile T-cells at single-nuclei resolution from frozen tissue revealing that vaccination altered gene expression signatures involved in inflammatory response and lymphocyte activation in the tumor microenvironment. Exposure to dexamethasone greatly suppressed immune reactivity, while PD-1 blockade enhanced local immune responses. With respect to efficacy, one third of patients survived longer than 24 months with one long-term survivor living &gt;40 months from time of diagnosis, exceeding survival of recently published trials. Thus, our study demonstrates the safety, feasibility, and preliminary clinical efficacy of a personalized multivalent neoantigen vaccination platform in a devastating cancer.
Return to Sport After Primary Hip Arthroscopic Surgery and Labral Repair in Female Athletes With Femoroacetabular Impingement: A Minimum 5-Year Follow-up
Kang, Louis , Levy, Bruce A. , Hevesi, Mario , Krych, Aaron J. , Okoroha, Kelechi R. , Mercurio, Angela M. , Cabarcas, Brandon C. , Hevesi, Mario , Krych, Aaron J , Okoroha, Kelechi R , Kang, Louis S , Ward, Gavin H.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | October 16, 2025 | Volume: 13 | Issue: 10 | Pages: No page available

10.1177/23259671251376515 | PMID 41122270 Get It

Background: Femoroacetabular impingement (FAI) is a common cause of hip pain in female athletes. There are limited data on midterm outcomes for female athletes undergoing hip arthroscopic surgery. Purpose: To evaluate return-to-sport rates and clinical outcomes in female athletes with FAI after primary hip arthroscopic surgery with labral repair and femoral osteochondroplasty. Study Design: Case series; Level of evidence, 4. Methods: A retrospective analysis of a single institution’s database was performed to identify female athletes who underwent primary hip arthroscopic surgery with labral repair and femoral osteochondroplasty from July 2011 to October 2019 with a minimum 5-year follow-up. Preoperative radiographs were evaluated for the lateral center-edge angle, Tonnis angle, Tonnis grade, and alpha angle. Patient-reported outcome measure (PROM) scores, including those for the modified Harris Hip Score, Hip Outcome Score, Tegner Activity Scale, and visual analog scale for pain, as well as patient satisfaction with surgery were analyzed postoperatively. Results: A total of 63 hips (27 left, 36 right) in 56 female patients (mean age, 21.6 ± 8.0 years; mean body mass index, 24.7 ± 4.8 kg/m 2 ) were included and followed for a mean of 8.4 ± 2.1 years (range, 5.0-13.2 years). Preoperatively, patients participated in basketball (n = 18), dance (n = 21), hockey (n = 8), and soccer (n = 12). Of the 56 patients, 41 attempted to return to sport. There were 28 (68%) female athletes who successfully returned to their preoperative sport. Of the total cohort, 21 (38%) patients cited non–hip-related factors for discontinuing their sport. All postoperative PROM scores improved significantly compared with preoperatively ( P ≤ .002) for patients with available preoperative data. Those who returned to sport had significantly improved Hip Outcome Score values compared with those who did not return to sport ( P ≤ .010). Conclusion: Female athletes who underwent primary hip arthroscopic surgery for FAI had significant improvements in PROM scores and moderate return-to-sport rates at a minimum 5-year follow-up. Most athletes discontinued sports because of non–hip-related factors, although hip-related issues were also cited. Our analysis highlights the need for thorough perioperative counseling and establishing appropriate patient expectations for female athletes before hip arthroscopic surgery.